Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-Adapted Melphalan, Thalidomide, and Dexamethasone in AL Amyloidosis
NCT00089167Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2002
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide in primary systemic amyloidosis, sponsored by Memorial Sloan Kettering Cancer Center. Started May 2002; status: completed.
02
Drugs
thalidomide
03
Conditions
primary systemic amyloidosis
Beyond the preview
Go deeper on NCT00089167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00089167.